Navigation Links
Cepheid Announces Preliminary 2013 Second Quarter Results
Date:7/11/2013

ical regarding Cepheid's or its management's intentions, beliefs, expectations and strategies for the future, including those relating to revenues and earnings per share for the Second Quarter, projected future revenues for both the Third Quarter and Fiscal Year 2013, consistency of product availability and delivery, sales organization productivity, improving gross margins, execution of manufacturing operations, product sales under the High Burden Developing Country (HBDC) program, commercial test and commercial system sales, and resolution of manufacturing scale-up issues.  Because such statements deal with future events, they are subject to various risks and uncertainties, and actual results could differ materially from the Company's current expectations. Factors that could cause actual results to differ materially include risks and uncertainties such as those relating to: our Second Quarter review process is not yet completed and actual Second Quarter results are subject to our standard quarterly close and review process; our ability to secure sufficient cartridge parts and increase manufacturing throughput of our cartridge production; our ability to manage our inventory levels; long sales cycles and variability in systems placements and reagent pull-through in the Company's HBDC program; our success in increasing commercial and HBDC sales and the effectiveness of our sales personnel; the performance and market acceptance of new products; sufficient customer demand, customer confidence in product availability and available capital budgets for our customers; our ability to develop new products and complete clinical trials successfully in a timely manner for new products; uncertainties related to the FDA regulatory and European regulatory processes; the level of testing at clinical customer sites, including for Healthcare Associated Infections (HAIs); the Company's ability to successfully introduce and sell products in clinical markets other than HAIs; the rat
'/>"/>
SOURCE Cepheid
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Cepheid Welcomes Executive Vice President of Global Operations
2. Cepheid Reports 2013 First Quarter Results
3. Testing Positive for Stability & Growth - Research Report on CombiMatrix Corporation, Cepheid, PerkinElmer, Inc., Life Technologies Corp. and Laboratory Corp. of America Holdings
4. Cepheid Announces Board of Directors Changes
5. Cepheid Reports 2012 Second Quarter Results
6. Cepheid Receives FDA Clearance for GeneXpert Infinity-80 System for Initial Use with Xpert Flu Assay
7. Cepheid Announces European Release of Xpert CT/NG and Xpert CT, Delivering Rapid Detection and Differentiation of Chlamydia and Gonorrhoeae
8. Diagnostic Marketing Association Names Cepheid 2011 Marketer of the Year
9. Cepheid Receives Grant to Develop Sample Processing and Amplification Methods for Detection of Bloodstream Bacteria
10. Cepheid to Webcast Upcoming Financial Presentations
11. Cepheid Reports Fourth Quarter and Full Year 2011 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... 2014 Today the National Institutes ... grants for the Brain Research through Advancing Innovative ... develop and revolutionize new methods of understanding the ... brain. This first round of grants totaling $46 ... allocated to more than 100 investigators in 15 ...
(Date:10/1/2014)... Francisco, California (PRWEB) October 01, 2014 ... from the National Science Foundation to expand their bioCAD/CAM ... to build and modify DNA. The Small Business Innovation ... commercialize the “j5” technology under exclusive license from the ... Joint BioEnergy Institute , an LBNL laboratory that ...
(Date:9/30/2014)... D.C., September 30, 2014 Applying a well-known ... researchers at Harvard University has demonstrated the ability ... -- work that holds promise for making future, ... detailing the sides of next-gen rocket ships and ... light passes through oil in water, it becomes ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 Shimadzu ... extensometer, an easy-to-use and highly precise tool for ... with considerable elongation. With 1000-mm maximum movement distance, ... percent for a gauge length of 10 mm. ... measurement accuracy above 50-mm stroke and within +/- ...
Breaking Biology Technology:NIH Awards 15 Grants to CHI Members for BRAIN Initiative Research 2NIH Awards 15 Grants to CHI Members for BRAIN Initiative Research 3TeselaGen Receives $750k NSF SBIR Phase II Award 2TeselaGen Receives $750k NSF SBIR Phase II Award 3Taking thin films to the extreme 2Shimadzu’s New Long-Travel Extensometer Increases Precision for Soft Material Testing 2
... UBS Global Life Sciences ... Conference, ... technology that accelerates the development,of life science and pharmaceutical products, today announced ... a top global,healthcare investment firm. MPM Capital also participated as a new ...
... 23 Arisyn Therapeutics Inc.,(Arisyn) announced today day ... Research, L.L.C. (UTR) a series of highly novel ... a variety of infectious organisms and cancer. Under ... intellectual property portfolio. In,return, UTR will receive a ...
... Global Certified Advantage Partnership streamlines management of patient ... data collected during ... Computer,Services Ltd. (NYSE: SAY ), a leading global ... working with Oracle,s,new Health Sciences Global Business Unit to ...
Cached Biology Technology:ForteBio, Inc. Closes $25 Million In Series C Financing 2ForteBio, Inc. Closes $25 Million In Series C Financing 3Arisyn Therapeutics Inc. Acquires Highly Novel Portfolio of Therapeutic Small Molecules for Infectious Disease and Cancer 2Arisyn Therapeutics Inc. Acquires Highly Novel Portfolio of Therapeutic Small Molecules for Infectious Disease and Cancer 3Satyam Partners with Oracle to Provide Clinical Development Applications 2Satyam Partners with Oracle to Provide Clinical Development Applications 3Satyam Partners with Oracle to Provide Clinical Development Applications 4
(Date:9/30/2014)... tourists visit the Mediterranean each year, but its ... on Earth. Almost 1,000 alien species, including fish, ... seas through human activities. In the open-access journal ... team of researchers analyzed data from a new ... show how the introduction of alien species has ...
(Date:9/30/2014)... San Diego, have completed the first comprehensive numerical simulation ... the pixels in an image as data points for ... The researchers, led by J.S. Chen, the William Prager ... Engineering at UC San Diego, presented their findings on ... in Pittsburgh this month. Chen also gave a keynote ...
(Date:9/30/2014)... by the Ocean Health Index rates the Earth,s ... health. In addition, for the first time, the ... regions beyond national jurisdiction (high-seas areas) all ... biodiversity and providing sustainable food sources. , In ... partnership led by scientists from UC Santa Barbara,s ...
Breaking Biology News(10 mins):Biodiversity in the Mediterranean is threatened by alien species 2First comprehensive meshfree numerical simulation of skeletal muscle tissue achieved 2Rating the planet's oceans 2Rating the planet's oceans 3
... Since Moffat and Ramsden for the first time discovered ... 1977, over the last two decades, great progress has ... Jrgensen and Mathiesen were the first authors to note ... in adult Australian parrots. Later, Roberson et al studied ...
...  DiscoveRx Corporation, through its BioSeek division, today announced ... assay platform for oncology research. Consisting of primary ... panel enables researchers to easily assess the phenotypic ... to better predict in vivo drug ...
... plants, the growth of organs such as roots, leaves ... reservoir-like compartments hold stem cells, which have the ability ... At Cold Spring Harbor Laboratory (CSHL), Professor David ... insights about how plants regulate their growth. This work ...
Cached Biology News:DiscoveRx Announces Launch of New Human Primary Cell-Based Panels for Oncology Research 2DiscoveRx Announces Launch of New Human Primary Cell-Based Panels for Oncology Research 3In odd-looking mutant, clues about how maize plants control stem cell number 2
Goat Anti-Horse IgG(T) Antibody, Unconjugated...
Goat polyclonal to STMN2 ( Abpromise for all tested applications). Antigen: Synthetic peptide: AKTAMAYKEK, corresponding to C terminal amino acids 2-11 of STMN2. Entrez Gene ID: 11075 Swi...
Mouse monoclonal antibody to RNase L...
Anti (porcine) Vitronectin...
Biology Products: